NCT05182931 2023-10-31
I-FIRST
Olivia Newton-John Cancer Research Institute
Phase 2 Unknown
Clinical Trials
13 trialsNCT04303403 2023-10-11
Study of Trametinib and Ruxolitinib in Colorectal Cancer and Pancreatic Adenocarcinoma
National Cancer Centre, Singapore
Phase 1 Unknown
NCT02858921 2023-08-30
Neo Trio
Melanoma Institute Australia
Phase 2 Unknown
NCT04965220 2023-08-09
HLX208 (BRAF V600E Inhibitor) in Combination With Trametinib in Patients With Advanced Solid Tumors
Shanghai Henlius Biotech
Phase 1 Unknown
NCT04619316 2023-06-22
ERRITI
University Hospital, Essen
Phase 2 Unknown
NCT03668431 2022-06-27
Dabrafenib + Trametinib + PDR001 In Colorectal Cancer
Massachusetts General Hospital
Phase 2 Unknown
NCT05171374 2022-06-01
RATIONALE
MelanomaPRO, Russia
Unknown
NCT03244956 2021-09-28
MERAIODE
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Unknown
NCT03754179 2021-04-28
COMBI-R2
Universitair Ziekenhuis Brussel
Phase 1/2 Unknown
NCT04554680 2021-03-05
Clinical Trial in RAI-Refractory Thyroid Carcinoma Evaluating BRAF & MEK Blockade for Re-differentiation Therapy
National University Hospital, Singapore
Phase 2 Unknown
NCT03088176 2020-10-12
Combining Talimogene Laherparepvec With BRAF and MEK Inhibitors in BRAF Mutated Advanced Melanoma
West Cancer Center
Phase 1 Unknown
NCT03543306 2018-06-01
Dabrafenib and Trametinib in Patients With Non-small Cell Lung Cancer Harboring V600E BRAF Mutation
Asan Medical Center
Phase 2 Unknown
NCT02625337 2017-09-15
IMPemBra
The Netherlands Cancer Institute
Phase 2 Unknown